Advertisement

2019 ESC guidelines on pulmonary embolism: Novelties and unanswered questions

  • Stavros Konstantinides
    Correspondence
    Corresponding author at: Centre for Thrombosis and Haemostasis, University Medical Centre Mainz, Langenbeckstrasse 1, Bldg. 403 55131 Mainz, Germany.
    Affiliations
    Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Germany

    Department of Cardiology, Democritus University of Thrace, Greece
    Search for articles by this author
Published:February 19, 2020DOI:https://doi.org/10.1016/j.ejim.2020.02.011
      The European Society of Cardiology (ESC) Guidelines for the diagnosis and management of acute pulmonary embolism (PE), developed in collaboration with the European Respiratory Society (ERS), were updated in 2019. The European Journal of Internal Medicine has published an elegantly written commentary by Vedovati and colleagues [
      • Vedovati M.C.
      • Giustozzi M.
      • Franco L.
      Beyond the guidelines: novelties, changes and unsolved issues from the 2019 ESC guidelines on pulmonary embolism.
      ], highlighting and critically reviewing some of the new recommendations. This article provides an excellent opportunity to explain and justify the main novelties and changes in the updated version of the ESC Guidelines, and also to put the remaining unanswered questions into perspective.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vedovati M.C.
        • Giustozzi M.
        • Franco L.
        Beyond the guidelines: novelties, changes and unsolved issues from the 2019 ESC guidelines on pulmonary embolism.
        EJIM. 2019;
        • Konstantinides S.V.
        • Meyer G.
        • Becattini C.
        • Bueno H.
        • Geersing G.J.
        • Harjola V.P.
        • et al.
        2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).
        Eur Heart J. 2020; 41: 543-603
        • Righini M.
        • Van Es J.
        • Den Exter P.L.
        • Roy P.M.
        • Verschuren F.
        • Ghuysen A.
        • et al.
        Age-adjusted d-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.
        JAMA. 2014; 311: 1117-1124
        • van der Hulle T.
        • Cheung W.Y.
        • Kooij S.
        • Beenen L.F.M.
        • van Bemmel T.
        • van Es J.
        • et al.
        Simplified diagnostic management of suspected pulmonary embolism (the years study): a prospective, multicentre, cohort study.
        Lancet. 2017; 390: 289-297
        • Konstantinides S.V.
        Diagnosis of pulmonary embolism: progress after many years.
        Lancet. 2017; 390: 210-211
        • Barco S.
        • Mahmoudpour S.H.
        • Planquette B.
        • Sanchez O.
        • Konstantinides S.V.
        • Meyer G
        Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis.
        Eur Heart J. 2019; 40: 902-910
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • Ahlsson A.
        • Atar D.
        • Casadei B.
        • et al.
        2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Europace. 2016; 18: 1609-1678
        • Pengo V.
        • Denas G.
        • Zoppellaro G.
        • Jose S.P.
        • Hoxha A.
        • Ruffatti A.
        • et al.
        Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
        Blood. 2018; 132: 1365-1371
        • Bauersachs R.
        • Langer F.
        • Kalka C.
        • Konstantinides S.
        • Klamroth R.
        • Oldenburg J.
        • et al.
        Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies.
        Vasa. 2019; 48: 483-486
        • Meneveau N.
        • Guillon B.
        • Planquette B.
        • Piton G.
        • Kimmoun A.
        • Gaide-Chevronnay L.
        • et al.
        Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases.
        Eur Heart J. 2018; 39: 4196-4204
        • Barco S.
        • Schmidtmann I.
        • Ageno W.
        • Bauersachs R.M.
        • Becattini C.
        • Bernardi E.
        • et al.
        Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor xa inhibitor rivaroxaban.
        Int Multicent Single-arm Clin Trial. Eur Heart J. 2019;
        • Young A.M.
        • Marshall A.
        • Thirlwall J.
        • Chapman O.
        • Lokare A.
        • Hill C.
        • et al.
        Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D).
        J Clin Oncol. 2018; 36: 2017-2023
        • Raskob G.E.
        • van Es N.
        • Verhamme P.
        • Carrier M.
        • Di Nisio M.
        • Garcia D.
        • et al.
        Edoxaban for the treatment of cancer-associated venous thromboembolism.
        N Engl J Med. 2018; 378: 615-624
        • Khorana A.A.
        • Noble S.
        • Lee A.Y.Y.
        • Soff G.
        • Meyer G.
        • O'Connell C.
        • et al.
        Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
        J Thromb Haemost. 2018; 16: 1891-1894
        • Agnelli G.
        • Becattini C.
        • Bauersachs R.
        • Brenner B.
        • Campanini M.
        • Cohen A.
        • et al.
        Apixaban versus Dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study.
        Thromb Haemost. 2018; 118: 1668-1678
        • Goodacre S.
        • Horspool K.
        • Nelson-Piercy C.
        • Knight M.
        • Shephard N.
        • Lecky F.
        • et al.
        The dipep study: an observational study of the diagnostic accuracy of clinical assessment, d-dimer and chest x-ray for suspected pulmonary embolism in pregnancy and postpartum.
        BJOG. 2019; 126: 383-392
        • Righini M.
        • Robert-Ebadi H.
        • Elias A.
        • Sanchez O.
        • Le Moigne E.
        • Schmidt J.
        • et al.
        Diagnosis of pulmonary embolism during pregnancy: a multicenter prospective management outcome study.
        Ann Intern Med. 2018; 169: 766-773
        • van der Pol L.M.
        • Tromeur C.
        • Bistervels I.M.
        • Ni Ainle F.
        • van Bemmel T.
        • Bertoletti L.
        • et al.
        Pregnancy-Adapted years algorithm for diagnosis of suspected pulmonary embolism.
        N Engl J Med. 2019; 380: 1139-1149
        • Steffel J.
        • Verhamme P.
        • Potpara T.S.
        • Albaladejo P.
        • Antz M.
        • Desteghe L.
        • et al.
        The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Eur Heart J. 2018; 39: 1330-1393